DUBLIN--(BUSINESS WIRE)--The "Epiomic Epidemiology Series: Mucopolysaccharidosis Type IV Forecast In 28 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is an inherited autosomal recessive genetic disorder in which glycosaminoglycans (GAGs) are accumulated in lysosomes due to mutations that cause loss of function of an enzyme responsible for degrading GAGs. The disorder manifests with multiple skeletal defects and has two subtypes, MPS IVA and MPS IVB, differing in the mutated gene. MPS IV constitutes a burden to the patients and their families as the disease progresses and the patients develop mobility impairment, breathing problems and corneal clouding.
This report provides the current prevalent population for MPS IV across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Switzerland, Ireland, Portugal, Czech Republic, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
MPS IV patients grouped by disease subtype, history of surgical procedures and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of MPS IV include:
- Recurrent upper respiratory tract infections
- Sleep apnoea
- Pulmonary hypertension
- Inguinal hernia
- Dental caries
- Vision impairment
- Hearing impairment and loss
Disturbances in urinary function
Key Topics Covered:
1. List Of Tables And Figures
3. Cause Of The Disease
4. Risk Factors & Prevention
5. Diagnosis Of The Disease
6. Variation By Geography/Ethnicity
7. Disease Prognosis & Clinical Course
8. Key Comorbid Conditions / Features Associated With The Disease
9. Methodology For Quantification Of Patient Numbers
10. Top-Line Prevalence For Mucopolysaccharidosis Type IV
11. Features Of Mucopolysaccharidosis Type IV Patients
12. MPS IVA
13. History Of Surgical Procedures In MPS IVA Patients
14. Comorbidities Of MPS IVA Patients
15. Abbreviations Used In The Report
16. Reports & Publications
17. Online Epidemiology Databases
18. Online Pharmaceutical Pricing Database
For more information about this report visit https://www.researchandmarkets.com/research/ggw2p9/epiomic?w=4